|
|
|
FDA Home Page | Search FDA Site
| FDA A-Z Index | Contact
FDA
The Prescription Drug User Fee Act (PDUFA) provides FDA with authority to collect increasing levels of fees for the review of human drug applications. PDUFA was reauthorized and extended through fiscal year 2007 by the Prescription Drug User Fee Amendments of 2002 (PDUFA III).
In July 1998 FDA made available a PDUFA II Five-Year Plan that presented the major assumptions FDA was making and the investments it intended to make over the five-year period 1998-2002 in order to achieve the new goals associated with the Prescription Drug User Fee Act of 1992 (PDUFA), as amended and extended through the year 2002 by the Food and Drug Modernization Act of 1997. That plan was updated several times.
The first PDUFA III Five-Year Plan was published in 2003 and serves as the blueprint for FDA's planned investment of the fee revenues and appropriations expected through FY 2007. The agency may update this plan if there are any significant events that merit substantial changes.
In our continuing efforts to maximize the availability and clarity of information about our review processes and plans, we are sharing these plans with all who have an interest and making them available to the public.
Office of Management and Systems
Attention: Frank P. Claunts
HF-20
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Please send a self-addressed adhesive label to assist that office
in processing your request.)